For patienter, som udviser virologisk respons ved uge 12, bør behandling fortsættes i en yderligere ni måneders periode (det vil sige i alt 48 uger).
For patients who exhibit virological response at week 12, treatment should be continued for another nine month period (i.e., a total of 48 weeks).